Activation of the μ-opiate receptor by Vitex agnus-castus methanol extracts: Implication for its use in PMS

Journal of Ethnopharmacology

Volumn 106, Issue 2, 2006, Pages 216-221

  Webster, D E ^a,b   Lu, J ^a   Chen, S N ^b   Farnsworth, N R ^b   Wang, Z Jim ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Endorphin; CNS; Opiate; PMS; Premenstrual syndrome; Vitex agnus castus

Indexed keywords

BETA ENDORPHIN; FATTY ACID; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); METHANOL; MU OPIATE RECEPTOR; VITEX AGNUS CASTUS EXTRACT;

ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG ACTIVATION; IC 50; NONHUMAN; PREMENSTRUAL SYNDROME; VITEX AGNUS CASTUS;

ANIMALS; BINDING, COMPETITIVE; CELL MEMBRANE; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; FEMALE; FRUIT; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); METHANOL; PLANT EXTRACTS; PREMENSTRUAL SYNDROME; RECEPTORS, OPIOID, MU; SOLVENTS; TRANSFECTION; VITEX;

CRICETULUS GRISEUS; VITEX AGNUS-CASTUS;

EID: 33646792988     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jep.2005.12.025     Document Type: Article

References (42)

1. Arden J., Segredo V., Wang Z., Lameh J., and Sadee W. Phosphorylation and agonist-specific intracellular trafficking of an epitope-tagged mu-opioid receptor expressed in HEK 293 cells. Journal of Neurochemistry 65 (1995) 1636-1645
2. Atmaca M., Kumru S., and Tezcan E. Fluoxetine versus Vitex agnus-castus extract in the treatment of premenstrual dysphoric disorder. Human Psychopharmacology 18 (2003) 191-195
3. Berger D., Schaffner W., Schrader E., Meier B., and Brattstrom A. Efficacy of Vitex agnus-castus L. extract Ze 440 in patients with pre-menstrual syndrome (PMS). Archives of Gynecology and Obstetrics 264 (2000) 150-153
4. Cheng Y., and Prusoff W. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochemical Pharmacology 22 (1973) 3099-3108
5. Chuong C., and Coulam C. Current view and beta-endorphin hypothesis. In: Gise I.H.K.N., and Berkowith R.L. (Eds). The Premenstrual Syndrome (1988), Churchill Livingstone, New York 75-95
6. Chuong C., Coulam C., Kao P., Bergstralh E., and Go V. Neuropeptide levels in premenstrual syndrome. Fertility and Sterility 44 (1985) 760-765
7. Chuong C.J., and Hsi B.P. Effect of naloxone on luteinizing hormone secretion in premenstrual syndrome. Fertility and Sterility 61 (1994) 1039-1044
8. Delitala G., Trainer P., Oliva O., Fanciulli G., and Grossman A. Opioid peptide and alpha-adrenoceptor pathways in the regulation of the pituitary-adrenal axis in man. Journal of Endocrinology 141 (1994) 163-168
9. Facchinetti F., Fioroni L., Martignoni E., Sances G., Costa A., and Genazzani A.R. Changes of opioid modulation of the hypothalamo-pituitary-adrenal axis in patients with severe premenstrual syndrome. Psychosomatic Medicine 56 (1994) 418-422
10. Facchinetti F., Martignoni E., Nappi G., Fioroni L., Sances G., and Genazzani A. Premenstrual failure of alpha-adrenergic stimulation on hypothalamus-pituitary responses in menstrual migraine. Psychosomatic Medicine 51 (1989) 550-558
11. Freeman E.W., Rickels K., Arrendondo F., Kao L.C., Pollack S.E., and Sondheimer S.T. Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. Journal of Clinical Psychopharmacology 19 (1999) 3-8
12. Giannini A., Martin D., and Turner C. Beta-endorphin decline in late luteal phase dysphoric disorder. International Journal of Psychiatry in Medicine 20 (1990) 279-284
13. Giannini A., Melemis S., Martin D., and Folts D. Symptoms of premenstrual syndrome as a function of beta-endorphin: two subtypes. Progress in Neuropsychopharmacology and Biological Psychiatry 18 (1994) 321-327
14. Giannini A., Price W.A., and Loiselle R.H. Beta-endorphin withdrawal: a possible cause of premenstrual tension syndrom. International Journal of Psychophysiology 1 (1984) 341-343
15. Giannini A., Sullivan B., Sarachene J., and Loiselle R. Clonidine in the treatment of premenstrual syndrome: a subgroup study. Journal of Clinical Psychiatry 49 (1988) 62-63
16. Halbreich U., and Endicott J. Possible involvement of endorphin withdrawal or imbalance in specific premenstrual syndromes and postpartum depression. Medical Hypotheses 7 (1981) 1045-1058
17. Halbreich U. The pathophysiologic background for current treatments of premenstrual syndromes. Current Psychiatry Reports 4 (2002) 429-434
18. Hoberg E. Phytochemical and Analytical Investigations of Vitex agnus-castus L. (1999), Swiss Federal Institute of Technology Zurich, Zurich p. 129
19. Hosohata K., Burkey T., Alfaro-Lopez J., Varga E., Hruby V., Roeske W., and Yamamura H.I. Endomorphin-1 and endomorphin-2 are partial agonists at the human mu-opioid receptor. European Journal of Pharmacology 346 (1998) 111-114
20. Ingkaninan K., von Frijtag Drabbe Kunzel J.K., Ijzerman A.P., and Verpoorte R. Interference of linoleic acid fraction in some receptor binding assays. Journal of Natural Products 62 (1999) 912-914
21. Jarry H., Leonhardt S., Gorkow C., and Wuttke W. In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of agus-castus: direct evidence for a dopaminergic principle by the dopamine receptor assay. Experimental and Clinical Endocrinology 102 (1994) 448-454
22. Kreek M., LaForge K., and Butelman E. Pharmacotherapy of addictions. Natural Reviews Drug Discovery 1 (2002) 710-726
23. Lauritzen C., Reuter H., Repges R., Bohnert K.-J., and Schmidt U. Treatment of premenstrual tension syndrome with Vitex agnus-castus: controlled, double-blind study versus pyridoxine. Phytomedicine 4 (1997) 183-189
24. Liu J., Burdette J.E., Sun Y., Deng S., Schlecht S.M., Zheng W., Nikolic D., Mahady G., van Breemen R.B., Fong H., Pezzuto J.M., Bolton J.L., and Farnsworth N.R. Isolation of linoleic acid as an estrogenic compound from the fruits of Vitex agnus-castus L. (chaste-berry). Phytomedicine 11 (2004) 18-23
25. Liu J., Burdette J.E., Xu H., Gu C., van Breemen R.B., Bhat K.P., Booth N., Constantinou A.I., Pezzuto J.M., Fong H.H., Farnsworth N.R., and Bolton J.L. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. Journal of Agricultural and Food Chemistry 49 (2001) 2472-2479
26. Loch E.G., Selle H., and Boblitz N. Treatment of premenstrual syndrome with a phytopharmaceutical formulation containing Vitex agnus-castus. Journal of Womens Health Gender Based Medicine 9 (2000) 315-320
27. Meier B., Berger D., Hoberg E., Sticher O., and Schaffner W. Pharmacological activities of Vitex agnus-castus extracts in vitro. Phytomedicine 7 (2000) 373-381
28. Meier B., and Hoberg E. Agni-casti fructus. Zeitschrift fur Phytotherapie 20 (1999) 140-158
29. Milewicz A., Gejdel E., Sworen H., Sienkiewicz K., Jedrzejak J., Teucher T., and Schmitz H. Vitex agnus-castus extract in the treatment of luteal phase defects due to latent hyperprolactinemia. Results of a randomized placebo-controlled double-blind study. Arzneimittelforschung 43 (1993) 752-756
30. Mortola J. Premenstrual syndrome. Trends in Endocrinology and Metabolism 7 (1996) 184-189
31. Narita M., Masami S., Mizoguchi H., Narita M., Yajima Y., Sakurada S., Tseng L., and Suzuki T. Up-regulation of μ-opioid receptor-mediated G-protein activation in protein kinase Cγ knockout mice following repeated naloxone treatment. Neuroscience Letters 338 (2003) 103-106
32. Rapkin A. A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. Psychoneuroendocrinology 28 Suppl. 3 (2003) 39-53
33. Schellenberg R. Treatment for the premenstrual syndrome with agnus-castus fruit extract: prospective, randomised, placebo controlled study. BMJ 322 (2001) 134-137
34. Selley D., Cao C., Sexton T., Schwegel J., Martin T., and Childers S. Mu-opioid receptor-mediated G-protein activation by heroin metabolites: evidence for greater efficacy of 6-monoacetylmorphine compared with morphine. Biochemistry and Pharmacology 62 (2001) 447-455
35. Silberstein S.D., and Merriam G.R. Physiology of the menstrual cycle. Cephalalgia 20 (2000) 148-154
36. Traynor J.R., and Nahorski S.R. Modulation by mu-opioid agonists of guanosine-5′-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Molecular Pharmacology 47 (1995) 848-854
37. Tulenheimo A., Laatikainen T., and Salminen K. Plasma beta-endorphin immunoreactivity in premenstrual tension. British Journal of Obstetrics and Gynaecology 94 (1987) 26-29
38. In: Upton R. (Ed). Chaste Tree Fruit, Vitex agnus-castus: Standards of Analysis, Quality Control, and Therapeutics (2001), American Herbal Pharmacopoeia, Santa Cruz, CA
39. Wang Z., Gardell L., Ossipov M., Vanderah T., Brennan M., Hochgeschwender U., Hruby V., Malan T., Lai J., and Porreca F. Pronociceptive actions of dynorphin maintain chronic neuropathic pain. Journal of Neuroscience 21 (2001) 1779-1786
40. Wang J., Johnson P., Persico A., Hawkins A., Griffin C., and Uhl G. Human mu-opiate receptor: cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. FEBS Letters 338 (1994) 217-222
41. Wang Z., and Sadee W. Tolerance to morphine at the mu-opioid receptor differentially induced by cAMP-dependent protein kinase activation and morphine. European Journal of Pharmacology 389 (2000) 165-171
42. Wuttke W., Jarry H., Christoffel V., Spengler B., and Seidlova-Wuttke D. Chaste tree (Vitex agnus-castus)-pharmacology and clinical indications. Phytomedicine 10 (2003) 348-357